JAMES JOYCE K.,O&rsquo,DONNELL PATRICK B,CORRINGHAM ROBERT E,O&rsquoDONNELL PATRICK B
申请号：
NZ59673910
公开号：
NZ596739A
申请日:
2010.05.14
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
596739 Disclosed herein is the use of N-(5-tert-butyl-isoxazol-3-yl)-N&rsquo；-{ 4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea (I), or a pharmaceutically acceptable salt or solvate thereof, in the treatment of a proliferative disease. Specifically disclosed are dosing, dosing schedules or dosing regimens such as administration of the compound on an empty stomach in a dosage of 12 mg to 200 mg of the compound per day. The proliferative disease may be a cancer, such as leukaemia. Additionally disclosed are specific patient groups, such as wherein the patient is relapsed or refractory.
